title: [Analysis of therapeutic effect and prognosis in patients with metastatic colorectal cancer and different K-ras status].
abstract: OBJECTIVE
  To evaluate the correlation of clinical effect and prognosis between patients with metastatic colorectal cancer (mCRC) and different K-ras status.
  
  
  METHODS
  The clinical characteristics, chemotherapeutic regimens and survival of 153 mCRC patients with different K-ras status were analyzed retrospectively.
  
  
  RESULTS
  The median overall survival (OS) in patients without K-ras mutation were 31.7 months, significantly longer than 21.3 months in the patients with K-ras mutation (P = 0.037). The median progression-free survival (PFS) and OS in patients who received chemotherapy followed by anti-EGFR antibody treatment were 11.5 and 39.3 months, respectively, significantly longer as compared with the PFS and OS in those received chemotherapy in combination with anti-EGFR antibody concomitantly (5.7, P = 0.02, and 28.7 months, P = 0.034, respectively).
  
  
  CONCLUSIONS
  K-ras status is a prognostic biomarker for mCRC patients treated with anti-EGFR antibody. The combination settings of anti-EGFR in combination with chemotherapy may improve survival of mCRC patients with wild-type K-ras status.
authors.affiliation: Cancer Center, Affiliated Hospital of Academy of Malitary Medical Sciences, Beijing 100071, China.
authors.forename: Fei-jiao
authors.initials: FJ
authors.lastname: Ge
authors.forename: Jian-zhi
authors.initials: JZ
authors.lastname: Liu
authors.forename: Shan-shan
authors.initials: SS
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Lie-jun
authors.initials: LJ
authors.lastname: Liu
authors.forename: Kai
authors.initials: K
authors.lastname: Yao
authors.forename: Chuan-hua
authors.initials: CH
authors.lastname: Zhao
authors.forename: Ya-Li
authors.initials: YL
authors.lastname: Fu
authors.forename: Li
authors.initials: L
authors.lastname: Lin
authors.forename: Jian-ming
authors.initials: JM
authors.lastname: Xu
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D011905:Genes, ras; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000077146:Irinotecan; D066246:ErbB Receptors; D002166:Camptothecin